Mometasone Furoate
FDA-approved product (ointment, topical), marketed as Asmanex Hfa, Asmanex Twisthaler, Elocon and 4 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Airway obstruction
- Allergic rhinitis
- Asthma
- Nasal Cavity Polyp
- Nasal congestion
- Nasal polyposis
- Seasonal allergic rhinitis
- Skin disease
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Corticosteroids, potent (group iii); Corticosteroids, potent, other combinations; Corticosteroids; Glucocorticoids
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA51.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli35.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae27.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis36.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Mometasone Furoate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Ozanimod HydrochlorideExisting use: Multiple sclerosis, Relapsing-remitting multiple sclerosis, Ulcerative colitis66.8% AI-predicted activityagainst MRSA7 registered studies
- Micafungin SodiumExisting use: Candidiasis66.8% AI-predicted activityagainst MRSA50+ registered studies
- AbemaciclibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more66.4% AI-predicted activityagainst MRSA50+ registered studies
- RisperidoneExisting use: Aggressive behavior, Autism, Bipolar disorder and 4 more66.4% AI-predicted activityagainst MRSA50+ registered studies
- Lazertinib MesylateExisting use: Non-small cell lung carcinoma66.1% AI-predicted activityagainst MRSANo documented evidence found
- Desmopressin AcetateExisting use: Central diabetes insipidus, Diabetes insipidus, Enuresis and 5 more65.8% AI-predicted activityagainst MRSA50+ registered studies
- Terazosin HydrochlorideExisting use: Benign prostatic hyperplasia65.8% AI-predicted activityagainst MRSA41 registered studies
- VemurafenibExisting use: Cancer, Cutaneous melanoma, Melanoma and 2 more65.8% AI-predicted activityagainst MRSA50+ registered studies
- Caspofungin AcetateExisting use: Aspergillosis, Candidemia, Candidiasis and 1 more65.5% AI-predicted activityagainst MRSA50+ registered studies
- VenetoclaxExisting use: Cancer, Chronic lymphocytic leukemia, Neoplasm65.5% AI-predicted activityagainst MRSA50+ registered studies
- Larotrectinib SulfateExisting use: Abdominal Neoplasms, Cancer, Metastasis and 1 more65.4% AI-predicted activityagainst MRSA5 registered studies
- SirolimusExisting use: Adenoma sebaceum, Angiofibroma, Cancer and 5 more65.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04431AM2)(COMPLETED)
NCT00381485 · start 2006-07-01
Registered record
- Registry ID
- NCT00381485
- Conditions
- Asthma
- Interventions
- Mometasone furoate/formoterol (MF/F) combination; Mometasone furoate/formoterol (MF/F) combination; Mometasone furoate MDI (MF MDI)
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2006-07-01
- Completion
- 2008-01-01
- Enrolment
- 834
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAsthmaInterventionMometasone furoate/formoterol (MF/F) combination; Mometasone furoate/formoterol (MF/F) combination; Mometasone furoate MDI (MF MDI)PhasePhase 3Registry statusCompletedMometasone Furoate on Sleep Disturbances in Subjects With Seasonal Allergic Rhinitis (Study P04608) (COMPLETED)
NCT00358527 · start 2006-05
Registered record
- Registry ID
- NCT00358527
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- Mometasone Furoate Nasal Spray (MFNS); Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2006-05
- Completion
- 2006-11
- Enrolment
- 401
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSeasonal Allergic RhinitisInterventionMometasone Furoate Nasal Spray (MFNS); PlaceboPhasePhase 4Registry statusCompletedPlacebo-controlled Trial With Nasonex for Nasal Obstruction Secondary to Adenoids Hypertrophy in Children (P04367)(TERMINATED)
NCT00553891 · start 2006-05
Registered record
- Registry ID
- NCT00553891
- Conditions
- Nasal Obstruction; Adenoids Hypertrophy; Adenoidectomy
- Interventions
- mometasone furoate nasal spray; placebo nasal spray
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Withdrawn
- Start
- 2006-05
- Completion
- 2009-10
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNasal Obstruction; Adenoids Hypertrophy; AdenoidectomyInterventionmometasone furoate nasal spray; placebo nasal sprayPhasePhase 4Registry statusWithdrawnA Study of Mometasone Furoate Nasal Spray in Perennial Allergic Rhinitis (Study P03748)(COMPLETED)
NCT00779545 · start 2004-04-08
Registered record
- Registry ID
- NCT00779545
- Conditions
- Rhinitis, Allergic, Perennial
- Interventions
- Placebo; Mometasone furoate; Mometasone furoate; Mometasone furoate; Mometasone furoate; Mometasone furoate
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2004-04-08
- Completion
- 2004-08-06
- Enrolment
- 455
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRhinitis, Allergic, PerennialInterventionPlacebo; Mometasone furoate; Mometasone furoate; Mometasone furoate +2 morePhasePhase 2Registry statusCompletedMometasone Furoate Nasal Spray for Treatment of Nasal Polyposis After Surgery (Study P03218)
NCT00731185 · start 2003-09-01
Registered record
- Registry ID
- NCT00731185
- Conditions
- Nasal Polyps
- Interventions
- Mometasone Furoate Nasal Spray; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2003-09-01
- Completion
- 2005-09-01
- Enrolment
- 162
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNasal PolypsInterventionMometasone Furoate Nasal Spray; PlaceboPhasePhase 3Registry statusCompleted